As of 2025-06-30, the EV/EBITDA ratio of Nurix Therapeutics Inc (NRIX) is -3.83. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NRIX's latest enterprise value is 811.52 mil USD. NRIX's TTM EBITDA according to its financial statements is -212.16 mil USD. Dividing these 2 quantities gives us the above NRIX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.6x - 13.5x | 13.2x |
| Forward P/E multiples | 21.9x - 31.0x | 25.4x |
| Fair Price | (59.84) - (36.57) | (52.71) |
| Upside | -614.1% - -414.2% | -552.9% |
| Date | EV/EBITDA |
| 2025-06-27 | -3.83 |
| 2025-06-26 | -3.90 |
| 2025-06-25 | -3.82 |
| 2025-06-24 | -3.94 |
| 2025-06-23 | -3.95 |
| 2025-06-20 | -3.77 |
| 2025-06-18 | -3.82 |
| 2025-06-17 | -3.74 |
| 2025-06-16 | -3.92 |
| 2025-06-13 | -3.93 |
| 2025-06-12 | -3.94 |
| 2025-06-11 | -4.18 |
| 2025-06-10 | -4.24 |
| 2025-06-09 | -4.15 |
| 2025-06-06 | -4.23 |
| 2025-06-05 | -4.13 |
| 2025-06-04 | -4.01 |
| 2025-06-03 | -3.98 |
| 2025-06-02 | -4.00 |
| 2025-05-30 | -3.46 |
| 2025-05-29 | -3.47 |
| 2025-05-28 | -3.25 |
| 2025-05-27 | -3.15 |
| 2025-05-23 | -3.14 |
| 2025-05-22 | -3.23 |
| 2025-05-21 | -3.16 |
| 2025-05-20 | -3.29 |
| 2025-05-19 | -3.06 |
| 2025-05-16 | -3.08 |
| 2025-05-15 | -3.04 |
| 2025-05-14 | -3.08 |
| 2025-05-13 | -3.14 |
| 2025-05-12 | -3.30 |
| 2025-05-09 | -3.06 |
| 2025-05-08 | -3.11 |
| 2025-05-07 | -2.98 |
| 2025-05-06 | -3.11 |
| 2025-05-05 | -3.57 |
| 2025-05-02 | -3.69 |
| 2025-05-01 | -3.65 |
| 2025-04-30 | -3.79 |
| 2025-04-29 | -3.75 |
| 2025-04-28 | -3.76 |
| 2025-04-25 | -3.80 |
| 2025-04-24 | -3.78 |
| 2025-04-23 | -3.81 |
| 2025-04-22 | -3.76 |
| 2025-04-21 | -3.43 |
| 2025-04-17 | -3.32 |
| 2025-04-16 | -3.16 |